Higher levels of tumor-infiltrating lymphocytes are linked to increased clinical benefit to trastuzumab plus chemotherapy in HER2-positive breast cancer.
Some older women with breast cancer receiving hormone therapy can omit postoperative radiotherapy.
The NeoALTTO study showed pathologic complete response increased survival in HER2-positive breast cancer.
The current system of AE reporting has modest sensitivity and a demonstrable false positive rate in cooperative group trials.
Telomere length may be prognostic of cognitive impairment in women after HCT.
ABT-199 (GDC-0199) demonstrated antitumor activity in patients with high-risk relapsed/refractory CLL and SLL.
Cytogenetic and molecular abnormalities may also be prognostic of post-relapse prognosis.
Invasive DFS was 92% after adjuvant trastuzumab plus docetaxel/carboplatin in patients with HER-2 positive breast cancer.
Ofatumumab plus chlorambucil prolongs PFS in older patients with CLL and comorbidities.
Long-term rituximab maintenance prolongs PFS in follicular lymphoma.
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|